Aldeyra Therapeutics (ALDX) Tops Q1 EPS by 3c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. LVS
6. QGEN
7. CSX
8. LRCX
9. NDAQ
10. BFH

Go back to Aldeyra Therapeutics (ALDX) Tops Q1 EPS by 3c

Aldeyra Therapeutics Reports First-Quarter 2022 Financial Results and Recent Corporate Highlights

May 5, 2022 7:00 AM EDT

Results from Phase 3 TRANQUILITY-2 Trial of Reproxalap in Dry Eye Disease Expected in Second Quarter of 2022 Results from Part 1 of Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy and Phase 2 Clinical Trial of ADX-2191 in Retinitis Pigmentosa Expected in the Second Half of 2022 Results from Phase 2 Clinical Trial of Oral RASP Inhibitor ADX-629 in Ethanol Toxicity Expected in the Second Half of 2022 Cash, Cash Equivalents, and Marketable Securities of $216.9 Million as of March 31, 2022 Management to Host Conference Call at 8:00 a.m. ET Today

LEXINGTON,... More